MCID: ADR005
MIFTS: 58

Adrenal Carcinoma

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Adrenal Carcinoma

MalaCards integrated aliases for Adrenal Carcinoma:

Name: Adrenal Carcinoma 12 38 15
Adrenal Cancer 12 77 54 56 74
Adrenal Gland Cancer 12 44 15
Adrenal Gland Neoplasms 45 74
Malignant Neoplasm of Adrenal Gland 12
Carcinoma of the Adrenal Gland 12
Tumor of the Adrenal Gland 12
Neoplasm of Adrenal Gland 12
Adrenocortical Carcinoma 74
Malignant Adrenal Tumor 12
Adrenal Gland Neoplasm 17
Adrenal Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3950 DOID:3953
KEGG 38 H00033
ICD9CM 36 194.0
MeSH 45 D000310
NCIt 51 C2859 C9338
SNOMED-CT 69 93665005
ICD10 34 C74 C74.9

Summaries for Adrenal Carcinoma

NIH Rare Diseases : 54 Adrenal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the adrenal glands (small glands that sit above each kidney). There are three different types of adrenal cancer which vary by location and the age at which they are often diagnosed:Adrenocortical carcinoma - The most common type of adrenal cancer which develops in the adrenal cortex (the outer part of the adrenal gland) Neuroblastoma - A childhood cancer that begins in the adrenal medulla (the inner part of the adrenal gland) Pheochromocytoma - A neuroendocrine tumor that begins in the adrenal medulla The signs and symptoms associated with the condition largely depend on if the cancer is 'functioning' (producing hormones) or 'nonfunctioning' (not producing hormones) and which hormones are present in excess. In most cases, the underlying cause of the condition is unknown. However, certain genetic conditions such as multiple endocrine neoplasia type 2, Li-Fraumeni syndrome, Von Hippel-Lindau syndrome, neurofibromatosis type I, and Carney complex are associated with an increased risk of developing adrenal tumors and cancer. Treatment may include a combination of surgery, hormone therapy, chemotherapy and radiation therapy.

MalaCards based summary : Adrenal Carcinoma, also known as adrenal cancer, is related to gangliocytoma and gastrointestinal stromal tumor, and has symptoms including fever and flank pain. An important gene associated with Adrenal Carcinoma is CRH (Corticotropin Releasing Hormone), and among its related pathways/superpathways are Cytochrome P450 - arranged by substrate type and Aldosterone synthesis and secretion. The drugs Citalopram and Autonomic Agents have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, kidney and cortex, and related phenotypes are Reduced mammosphere formation and growth/size/body region

Disease Ontology : 12 An endocrine gland cancer located in the adrenal glands which are located above the kidneys.

MedlinePlus : 44 Your adrenal, or suprarenal, glands are located on the top of each kidney. These glands produce hormones that you can't live without, including sex hormones and cortisol, which helps you respond to stress and has many other functions. A number of disorders can affect the adrenal glands, including tumors. Tumors can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. Most adrenal gland tumors are benign. They usually do not cause symptoms and may not require treatment. Malignant adrenal gland cancers are uncommon. Types of tumors include Adrenocortical carcinoma - cancer in the outer part of the gland Neuroblastoma, a type of childhood cancer Pheochromocytoma - a rare tumor that is usually benign Symptoms depend on the type of cancer you have. Treatments may include surgery, chemotherapy, or radiation therapy.

Wikipedia : 77 An adrenal tumor or adrenal mass is any benign or malignant neoplasms of the adrenal gland, several of... more...

Related Diseases for Adrenal Carcinoma

Diseases related to Adrenal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 180)
# Related Disease Score Top Affiliating Genes
1 gangliocytoma 30.2 CRH POMC SYP
2 gastrointestinal stromal tumor 29.5 ENO2 IGF2 MEN1 SYP
3 hypoaldosteronism 29.5 CYP11B2 POMC REN
4 adenoma 29.1 CYP11B2 CYP21A2 MEN1 POMC
5 pheochromocytoma 28.7 CRH ENO2 MEN1 POMC REN SYP
6 hypertension, essential 28.7 CYP11B1 CYP11B2 MEN1 REN
7 conn's syndrome 28.1 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
8 adrenal adenoma 27.6 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
9 lipoid congenital adrenal hyperplasia 27.5 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 NR5A1
10 adrenocortical carcinoma, hereditary 27.2 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
11 adrenal neuroblastoma 11.2
12 adrenal medulla cancer 11.2
13 multiple endocrine neoplasia, type iib 11.1
14 von hippel-lindau syndrome 11.1
15 carotid body cancer 10.5 ENO2 SYP
16 malignant sertoli cell tumor 10.4 ENO2 SYP
17 urinary bladder small cell neuroendocrine carcinoma 10.4 ENO2 SYP
18 auditory system cancer 10.4 ENO2 SYP
19 sinonasal undifferentiated carcinoma 10.4 ENO2 SYP
20 cutaneous ganglioneuroma 10.4 ENO2 SYP
21 extrahepatic bile duct adenocarcinoma 10.4 ENO2 SYP
22 small cell carcinoma of the bladder 10.4 ENO2 SYP
23 papillary tumor of the pineal region 10.4 ENO2 SYP
24 sensory organ benign neoplasm 10.4 ENO2 SYP
25 adenomatoid tumor 10.4
26 orbital cancer 10.4 ENO2 SYP
27 middle ear adenoma 10.4 ENO2 SYP
28 pulmonary large cell neuroendocrine carcinoma 10.4 ENO2 SYP
29 gallbladder small cell carcinoma 10.4 ENO2 SYP
30 allergic encephalomyelitis 10.4 CRH POMC
31 atypical follicular adenoma 10.4 ENO2 SYP
32 central nervous system primitive neuroectodermal neoplasm 10.4 ENO2 SYP
33 cerebellum cancer 10.4 ENO2 SYP
34 clear cell ependymoma 10.4 ENO2 SYP
35 cauda equina neoplasm 10.4 ENO2 SYP
36 hypothalamic disease 10.4 CRH POMC
37 endometrial small cell carcinoma 10.4 ENO2 SYP
38 lymphocytic hypophysitis 10.4 ENO2 POMC
39 gastric leiomyosarcoma 10.4 ENO2 IGF2
40 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 10.4 CYP21A2 POMC
41 transsexualism 10.4 CYP17A1 CYP21A2
42 extraosseous chondrosarcoma 10.4 ENO2 SYP
43 subependymal glioma 10.4 ENO2 SYP
44 lung oat cell carcinoma 10.4 ENO2 POMC
45 malignant teratoma 10.4 ENO2 SYP
46 pituitary carcinoma 10.4 CRH POMC
47 astroblastoma 10.4 ENO2 SYP
48 bronchus cancer 10.4 ENO2 POMC
49 neuroblastoma 1 10.4
50 hereditary paraganglioma-pheochromocytoma syndromes 10.4

Graphical network of the top 20 diseases related to Adrenal Carcinoma:



Diseases related to Adrenal Carcinoma

Symptoms & Phenotypes for Adrenal Carcinoma

UMLS symptoms related to Adrenal Carcinoma:


fever, flank pain

GenomeRNAi Phenotypes related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CYP11B1 CYP21A2 IGF2 LIAS MEN1 POMC

MGI Mouse Phenotypes related to Adrenal Carcinoma:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.28 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 ENO2
2 behavior/neurological MP:0005386 10.24 CRH CYP11A1 CYP11B1 CYP17A1 ENO2 GRN
3 homeostasis/metabolism MP:0005376 10.21 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 GRN
4 cellular MP:0005384 10.16 CRH CYP11A1 CYP11B1 CYP17A1 ENO2 GRN
5 cardiovascular system MP:0005385 10.13 CYP11A1 CYP11B1 CYP11B2 IGF2 LIAS MEN1
6 endocrine/exocrine gland MP:0005379 10.09 CRH CYP11A1 CYP11B1 CYP11B2 IGF2 MEN1
7 mortality/aging MP:0010768 10.03 CYP11A1 CYP11B1 CYP17A1 GRN IGF2 LIAS
8 nervous system MP:0003631 9.93 CRH CYP11A1 CYP11B2 ENO2 GRN IGF2
9 liver/biliary system MP:0005370 9.87 CRH CYP11A1 CYP11B2 GRN IGF2 MEN1
10 renal/urinary system MP:0005367 9.43 CRH CYP11B1 CYP11B2 IGF2 POMC REN
11 reproductive system MP:0005389 9.28 CYP11A1 CYP11B2 CYP17A1 GRN IGF2 MEN1

Drugs & Therapeutics for Adrenal Carcinoma

Drugs for Adrenal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4 59729-33-8 2771
2 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
3 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
4 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
5 Neurotransmitter Uptake Inhibitors Phase 4
6 Cholinergic Agents Phase 4
7 Analgesics Phase 4,Phase 3
8 Psychotropic Drugs Phase 4
9 Analgesics, Non-Narcotic Phase 4
10 Antidepressive Agents, Second-Generation Phase 4
11 Parasympatholytics Phase 4
12 Serotonin Agents Phase 4
13 Muscarinic Antagonists Phase 4
14 Serotonin Uptake Inhibitors Phase 4
15 Antiparkinson Agents Phase 4
16 Antidepressive Agents Phase 4
17 Cholinergic Antagonists Phase 4
18 Interleukin-2 Phase 4
19
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
20
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
21
Racepinephrine Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
22
Mecasermin Approved, Investigational Phase 3 68562-41-4
23
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
24
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
25
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
26
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
27
Mitotane Approved Phase 3,Phase 2,Not Applicable 53-19-0 4211
28
Lenograstim Approved, Investigational Phase 3 135968-09-1
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
30
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-23-7 5754
31
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
32
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-03-3
33
Etomidate Approved Phase 3,Phase 1,Phase 2 33125-97-2 667484 36339
34
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
35
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
36
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
37 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
38 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1
39 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Cola Phase 3,Phase 2,Phase 1,Early Phase 1
41 Epinephryl borate Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Antimitotic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
43 Bronchodilator Agents Phase 3,Phase 2,Not Applicable,Early Phase 1
44 Adrenergic alpha-Agonists Phase 3,Phase 2,Not Applicable,Early Phase 1
45 Adrenergic Agonists Phase 3,Phase 2,Not Applicable,Early Phase 1
46 Adrenergic beta-Agonists Phase 3,Phase 2,Not Applicable,Early Phase 1
47 Sympathomimetics Phase 3,Phase 2,Not Applicable,Early Phase 1
48 Respiratory System Agents Phase 3,Phase 2,Not Applicable,Early Phase 1
49 Vasoconstrictor Agents Phase 3,Phase 2,Not Applicable,Early Phase 1
50 Mydriatics Phase 3,Phase 2,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
2 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
3 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
4 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
5 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
6 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
7 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
8 Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
9 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
10 Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Recruiting NCT00777244 Phase 3 MITOTANE
11 Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia Recruiting NCT02010957 Phase 3
12 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
13 Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
14 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
15 Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
16 Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
17 Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
18 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
19 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
20 Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
21 Sunitinib in Refractory Adrenocortical Carcinoma Completed NCT00453895 Phase 2 Sunitinib
22 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
23 Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
24 A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients Completed NCT01262235 Phase 1, Phase 2 TKM-080301
25 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
26 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Completed NCT02468193 Phase 2 Osilodrostat
27 A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent Completed NCT00264433 Phase 2 ADH -1 (Exherin™)
28 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
29 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
30 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Completed NCT02804750 Phase 2 CORT125134
31 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
32 Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
33 Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
34 Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
35 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
36 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
37 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
38 Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Recruiting NCT03604198 Phase 2 relacorilant
39 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
40 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
41 Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting NCT02673333 Phase 2 Pembrolizumab
42 Cabozantinib in Advanced Adrenocortical Carcinoma Not yet recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
43 S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
44 Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Terminated NCT02720484 Phase 2 Nivolumab
45 IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Terminated NCT00778817 Phase 2 mitotane
46 Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
47 Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism Terminated NCT02001051 Phase 2
48 Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Withdrawn NCT00469469 Phase 2 Bevacizumab
49 Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
50 Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin

Search NIH Clinical Center for Adrenal Carcinoma

Cochrane evidence based reviews: adrenal gland neoplasms

Genetic Tests for Adrenal Carcinoma

Anatomical Context for Adrenal Carcinoma

MalaCards organs/tissues related to Adrenal Carcinoma:

42
Adrenal Gland, Kidney, Cortex, Adrenal Cortex, Lung, Testes, Pituitary

The Foundational Model of Anatomy Ontology organs/tissues related to Adrenal Carcinoma:

20
The Adrenal Gl

Publications for Adrenal Carcinoma

Articles related to Adrenal Carcinoma:

(show top 50) (show all 237)
# Title Authors Year
1
ADRENAL CARCINOMA IN CHILDREN: LONGITUDINAL STUDY IN MINAS GERAIS, BRAZIL. ( 30066822 )
2019
2
Hypertensive choroidopathy and adrenal carcinoma: A new association. ( 30337095 )
2019
3
Erythrocytosis as the first manifestation of adrenal carcinoma. ( 30859743 )
2019
4
CaseReport: Aldosterone-secreting adrenal carcinoma complicating longstanding hypertension. ( 31089198 )
2019
5
Treatment and management of adrenal cancer in a specialized Australian endocrine surgical unit: approaches, outcomes and lessons learnt. ( 30710432 )
2019
6
Cushing syndrome due to adrenal carcinoma. ( 29633121 )
2018
7
Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study. ( 30533000 )
2018
8
Sarcomatoid Adrenal Carcinoma: Case Report with Contribution to Pathogenesis. ( 27688079 )
2017
9
Mixed corticomedullary adrenal carcinoma - case report: Comparison in features, treatment and prognosis with the other two reported cases. ( 28199934 )
2017
10
Aggressive adrenal carcinoma in a young patient with Multiple Endocrine Neoplasia 1 syndrome. ( 28625514 )
2017
11
Surgical treatment of adrenal carcinoma. ( 28754418 )
2017
12
Adrenohepatic fusion: Adhesion or invasion in primary virilizant giant adrenal carcinoma? Implications for surgical resection. Two case report and review of the literature. ( 26684865 )
2016
13
Evaluation of a large adrenal carcinoma with 3D reconstruction of computed tomography images: A case report and literature review. ( 27567750 )
2016
14
Diagnosis and Management of Hereditary Adrenal Cancer. ( 27075352 )
2016
15
Laparoscopic Adrenalectomy for Adrenal Cancer-A Systematic Review. ( 27215723 )
2016
16
Piecing Together the Adrenal Cancer Puzzle. ( 27246538 )
2016
17
Pathology in practice. Mediastinal thyroid follicular carcinoma and adrenal carcinoma. ( 25587729 )
2015
18
A Rare Presentation of Primary Hyperparathyroidism with Concurrent Aldosterone-Producing Adrenal Carcinoma. ( 26161274 )
2015
19
Rare cardiac involvement in adrenal carcinoma. ( 26301653 )
2015
20
RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. ( 25497672 )
2015
21
Exploiting the Unusual to Find the Rare: Novel Steroid Metabolites Pinpoint Adrenal Cancer Patients. ( 26069029 )
2015
22
Histoplasmosis mimicking adrenal carcinoma. ( 24600775 )
2014
23
Incidental renal cell carcinoma originating from a native kidney after en-bloc resection for adrenal carcinoma in a kidney transplant recipient. ( 24656033 )
2014
24
Senile primary aldosteronism associated with adrenal carcinoma. ( 24796641 )
2014
25
Functional ectopic adrenal carcinoma in a dog. ( 25183891 )
2014
26
Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis. ( 25520849 )
2014
27
Adrenal cancer in 2013: Time to individualize treatment for adrenocortical cancer? ( 24393782 )
2014
28
Management of adrenal cancer: a 2013 update. ( 24458831 )
2014
29
Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature. ( 23275528 )
2013
30
Mixed corticomedullary adrenal carcinoma. ( 23435808 )
2013
31
Adrenal carcinoma: a retrospective analysis of our series. ( 23540614 )
2013
32
Neoadjuvant chemotherapy and salvage surgery for an aldosterone-producing adrenal carcinoma with inferior vena cava thrombus: case report and literature review. ( 23810165 )
2013
33
A case of androgen-secreting adrenal carcinoma with non-classical congenital adrenal hyperplasia. ( 24251173 )
2013
34
A giant adrenal pseudocyst mimicking an adrenal cancer: case report and review of the literature. ( 23548497 )
2013
35
Successful pulmonary thrombectomy for malignant tumor thrombus after adrenal cancer resection. ( 24080241 )
2013
36
The role of radiation therapy in the management of adrenal carcinoma and adrenal metastases. ( 22488095 )
2012
37
Giant adrenal carcinoma associated with renal vein and inferior vena cava thrombus. Case report and literature review. ( 22732784 )
2012
38
Feminizing adrenal carcinoma presenting with heart failure and ventricular tachycardia. ( 22937299 )
2012
39
Analysis of energy utilization and body composition in kidney, bladder, and adrenal cancer patients. ( 20884257 )
2012
40
Adrenal cancer: scientific advances. ( 22108436 )
2012
41
Systemic therapy for advanced adrenal cancer. ( 22488742 )
2012
42
Management of adjuvant mitotane therapy following resection of adrenal cancer. ( 22706605 )
2012
43
Structural requirements for mitotane activity: development of analogs for treatment of adrenal cancer. ( 22753730 )
2012
44
The ENSAT registry: a digital repository supporting adrenal cancer research. ( 22797043 )
2012
45
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ( 22997446 )
2012
46
Effect of combined lignan phytoestrogen and melatonin treatment on secretion of steroid hormones by adrenal carcinoma cells. ( 21529220 )
2011
47
Normal delivery following resection of an androgen-secreting adrenal carcinoma. ( 29699081 )
2011
48
Triptolide induces apoptosis in human adrenal cancer NCI-H295 cells through a mitochondrial-dependent pathway. ( 21152873 )
2011
49
Chemotherapy for advanced adrenal cancer: improvement from a molecular approach? ( 21883840 )
2011
50
KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer. ( 22096502 )
2011

Variations for Adrenal Carcinoma

Cosmic variations for Adrenal Carcinoma:

9 (show top 50) (show all 77)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM14283 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.491A>G p.Q164R 3:10149814-10149814 0
2 COSM17662 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.492G>T p.Q164H 3:10149815-10149815 0
3 COSM18097 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.482G>A p.R161Q 3:10149805-10149805 0
4 COSM144972 VHL adrenal gland,NS,pheochromocytoma,benign c.245G>T p.R82L 3:10142092-10142092 0
5 COSM14321 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.227T>A p.F76Y 3:10142074-10142074 0
6 COSM144971 VHL adrenal gland,NS,pheochromocytoma,benign c.244C>G p.R82G 3:10142091-10142091 0
7 COSM6444479 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.260T>C p.V87A 3:10142107-10142107 0
8 COSM144975 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.475A>G p.K159E 3:10149798-10149798 0
9 COSM100047 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.389T>G p.V130G 3:10146562-10146562 0
10 COSM14311 VHL adrenal gland,NS,pheochromocytoma,benign c.499C>T p.R167W 3:10149822-10149822 0
11 COSM17982 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.496G>T p.V166F 3:10149819-10149819 0
12 COSM236660 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.250G>C p.V84L 3:10142097-10142097 0
13 COSM17988 VHL adrenal gland,NS,pheochromocytoma,benign c.341-1G>T p.? 3:10146513-10146513 0
14 COSM45444 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.587G>T p.R196L 17:7674944-7674944 0
15 COSM43555 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.736A>G p.M246V 17:7674227-7674227 0
16 COSM43931 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.523C>A p.R175S 17:7675089-7675089 0
17 COSM11286 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1015G>T p.E339* 17:7670694-7670694 0
18 COSM10801 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.404G>A p.C135Y 17:7675208-7675208 0
19 COSM10659 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.817C>T p.R273C 17:7673803-7673803 0
20 COSM11071 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1009C>T p.R337C 17:7670700-7670700 0
21 COSM44175 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.644G>C p.S215T 17:7674887-7674887 0
22 COSM966 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1900T>C p.C634R 10:43114500-43114500 0
23 COSM965 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.2753T>C p.M918T 10:43121968-43121968 0
24 COSM326321 RB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,cortisol producing c.1994T>G p.L665R 13:48459721-48459721 0
25 COSM225014 RB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.1960G>A p.V654M 13:48456349-48456349 0
26 COSM4167506 PRKACA adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.617T>G p.L206R 19:14097604-14097604 0
27 COSM132853 NFE2L2 kidney,NS,carcinoma,Type 2 c.245A>G p.E82G 2:177234072-177234072 0
28 COSM220089 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1885G>A p.Q616fs*4 17:31225134-31225134 0
29 COSM329092 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1721+3A>T p.A548fs*13 17:31221932-31221932 0
30 COSM30670 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7646C>G p.S2549* 17:31356490-31356490 0
31 COSM329090 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 0
32 COSM5885098 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.5665G>T p.E1889* 17:31330351-31330351 0
33 COSM329093 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1722-1G>A p.? 17:31223443-31223443 0
34 COSM330587 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.R69Xfs*7 17:31159009-31159009 0
35 COSM327926 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.3158C>A p.S1053* 17:31230886-31230886 0
36 COSM327927 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7582C>T p.Q2528* 17:31352381-31352381 0
37 COSM33676 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.6855C>A p.Y2285* 17:31338739-31338739 0
38 COSM3402726 NF1 adrenal gland,NS,pheochromocytoma,benign c.1307C>A p.S436* 17:31206286-31206286 0
39 COSM1710108 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7300C>T p.Q2434* 17:31349230-31349230 0
40 COSM330588 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.2409+1G>A p.A776_Q803del 17:31227607-31227607 0
41 COSM329089 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 0
42 COSM707 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.3029C>T p.T1010I 7:116771936-116771936 0
43 COSM5967149 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.607T>A p.S203T 7:116699691-116699691 0
44 COSM5946188 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.352A>T p.M118L 7:116699436-116699436 0
45 COSM4445248 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1132G>T p.E378* 11:64805688-64805688 0
46 COSM4445249 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.808C>A p.L270M 11:64807195-64807195 0
47 COSM4445247 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.812G>C p.G271A 11:64807191-64807191 0
48 COSM4445246 MED12 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.4857G>T p.K1619N 23:71134842-71134842 0
49 COSM499 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.182A>G p.Q61R 11:533874-533874 0
50 COSM496 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.181C>A p.Q61K 11:533875-533875 0

Expression for Adrenal Carcinoma

Search GEO for disease gene expression data for Adrenal Carcinoma.

Pathways for Adrenal Carcinoma

Pathways related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 POMC
2
Show member pathways
12.62 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 NR5A1
3 12.25 CYP11A1 CYP17A1 ENO2 STAR
4
Show member pathways
11.47 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
5 11.4 CRH CYP11A1 CYP11B1 CYP21A2 POMC STAR
6 11.23 CYP11A1 CYP17A1 STAR
7
Show member pathways
11.11 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 POMC
8
Show member pathways
10.97 CYP11B1 CYP11B2 CYP17A1 CYP21A2
9 10.25 CRH POMC

GO Terms for Adrenal Carcinoma

Biological processes related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.86 CCNB1 CRH REN STAR
2 steroid metabolic process GO:0008202 9.8 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
3 male gonad development GO:0008584 9.72 NR5A1 REN STAR
4 cholesterol metabolic process GO:0008203 9.71 CYP11A1 CYP11B1 CYP11B2 STAR
5 regulation of blood pressure GO:0008217 9.69 CYP11B1 POMC REN
6 cellular response to peptide hormone stimulus GO:0071375 9.67 CYP11A1 CYP11B1 CYP11B2 MEN1
7 adrenal gland development GO:0030325 9.58 CRH NR5A1
8 regulation of neuronal synaptic plasticity GO:0048168 9.58 STAR SYP
9 response to corticosterone GO:0051412 9.57 CRH STAR
10 C21-steroid hormone biosynthetic process GO:0006700 9.56 CYP11A1 CYP11B1 CYP11B2 STAR
11 cellular response to potassium ion GO:0035865 9.54 CYP11B1 CYP11B2
12 regulation of steroid biosynthetic process GO:0050810 9.52 NR5A1 STAR
13 diterpenoid metabolic process GO:0016101 9.49 CRH STAR
14 mineralocorticoid biosynthetic process GO:0006705 9.48 CYP11B2 CYP21A2
15 aldosterone biosynthetic process GO:0032342 9.46 CYP11B1 CYP11B2
16 sterol metabolic process GO:0016125 9.46 CYP11A1 CYP11B1 CYP11B2 CYP21A2
17 cortisol biosynthetic process GO:0034651 9.43 CYP11B1 CYP11B2
18 steroid biosynthetic process GO:0006694 9.43 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 STAR
19 glucocorticoid biosynthetic process GO:0006704 9.1 CRH CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2

Molecular functions related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.77 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
2 hormone activity GO:0005179 9.58 CRH IGF2 POMC
3 heme binding GO:0020037 9.55 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
4 insulin-like growth factor receptor binding GO:0005159 9.43 IGF2 REN
5 iron ion binding GO:0005506 9.35 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
6 corticosterone 18-monooxygenase activity GO:0047783 9.32 CYP11B1 CYP11B2
7 steroid 11-beta-monooxygenase activity GO:0004507 9.26 CYP11B1 CYP11B2
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.02 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2

Sources for Adrenal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....